<i>Bcl-xL</i> as a poor prognostic biomarker and predictor of response to adjuvant chemotherapy specifically in <i>BRAF</i> -mutant stage II and III colon cancer
Philip D. Dunne(Queen's University Belfast), Mark Lawler(Queen's University Belfast)
Cited by 11
Related Papers
<i>Bcl-xL</i> as a poor prognostic biomarker and predictor of response to adjuvant chemotherapy specifically in <i>BRAF</i> -mutant stage II and III colon cancer
|bioRxiv (Cold Spring Harbor Laboratory)|2017|1